Investment Analysts’ Recent Ratings Changes for Waters (WAT)

A number of firms have modified their ratings and price targets on shares of Waters (NYSE: WAT) recently:

  • 1/8/2018 – Waters had its “hold” rating reaffirmed by analysts at Barclays PLC. They now have a $202.00 price target on the stock.
  • 1/6/2018 – Waters was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Waters Corp. has an excellent earnings history, having surpassed estimates in each of the trailing four quarters. Going forward, the company believes that stable demand from pharmaceutical business, steady recurring revenues, strength in Asia and modest recovery in industrial markets will accelerate its momentum. Based on these dynamics, the company is expecting strong mid-single-digit constant currency sales increase. Even the government and academic markets have returned to the growth track after sustained weakness. However, the company’s growth will likely be hindered by contracting demand in the Americas. Waters Corp. also intends to increase its spending on research and development in the coming quarters, which, although beneficial in the long run, will push expenses higher and hurt immediate profits. Further, shares of Waters Corp. have underperformed the industry’s average return over past six months.”
  • 1/5/2018 – Waters is now covered by analysts at BTIG Research. They set a “buy” rating and a $230.00 price target on the stock.
  • 1/3/2018 – Waters is now covered by analysts at Evercore ISI. They set an “in-line” rating and a $198.00 price target on the stock.
  • 12/26/2017 – Waters was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $217.00 price target on the stock. According to Zacks, “Waters Corp. has an excellent earnings history, having surpassed estimates in each of the trailing four quarters. Going forward, the company believes that stable demand from pharmaceutical business, steady recurring revenues, strength in Asia and modest recovery in industrial markets will accelerate its momentum. Based on these dynamics, the company is expecting strong mid-single-digit constant currency sales increase. Even the government and academic markets have returned to the growth track after sustained weakness. Moreover, the company has been benefiting hugely from both of its LC and LC/MS platforms. Further, shares of the company have outperformed the industry’s average return over past year. However, the company’s growth will likely be hindered by contracting demand in the Americas. Also, currency headwinds are expected to somewhat hinder the company’s sales, going forward.”
  • 12/4/2017 – Waters was upgraded by analysts at Morgan Stanley from an “underweight” rating to an “equal weight” rating. They now have a $192.00 price target on the stock.

Waters Co. (WAT) traded down $0.81 during trading hours on Tuesday, hitting $208.94. The stock had a trading volume of 512,190 shares, compared to its average volume of 361,890. Waters Co. has a 52 week low of $137.72 and a 52 week high of $211.65. The company has a market capitalization of $16,620.00, a price-to-earnings ratio of 30.82, a PEG ratio of 2.81 and a beta of 0.82. The company has a debt-to-equity ratio of 0.66, a current ratio of 6.16 and a quick ratio of 5.71.

Waters (NYSE:WAT) last issued its quarterly earnings data on Tuesday, October 24th. The medical instruments supplier reported $1.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.74 by $0.03. Waters had a return on equity of 23.61% and a net margin of 24.34%. The business had revenue of $565.58 million during the quarter, compared to analyst estimates of $555.25 million. During the same period in the prior year, the company posted $1.57 EPS. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. sell-side analysts forecast that Waters Co. will post 7.42 EPS for the current fiscal year.

In related news, Director Thomas P. Salice sold 3,500 shares of the stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $200.03, for a total value of $700,105.00. Following the completion of the transaction, the director now directly owns 20,349 shares of the company’s stock, valued at approximately $4,070,410.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joann A. Reed sold 1,386 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $194.07, for a total value of $268,981.02. The disclosure for this sale can be found here. Insiders sold a total of 93,159 shares of company stock valued at $18,412,172 over the last three months. Corporate insiders own 5.07% of the company’s stock.

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.

Receive News & Ratings for Waters Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply